We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisory Panel Backs Approval of Pfizer, Affymax Drugs
FDA Advisory Panel Backs Approval of Pfizer, Affymax Drugs
December 9, 2011
An FDA advisory committee unanimously backed Pfizer’s kidney cancer drug Inlyta as a second-line treatment for patients with advanced renal cell carcinoma (RCC).